Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2017-10-09 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
七届二十八次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed by the board of directors of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) during their 28th meeting of the 7th board. It includes proposals for amending the company's articles of association, nomination of candidates for the 8th board of directors and independent directors, and the scheduling of an extraordinary shareholders' meeting. The document contains detailed biographies and declarations of the nominated directors and independent directors, including their qualifications and compliance with relevant laws and regulations. The content focuses on board and management changes and nominations rather than financial results, audit opinions, or shareholder voting results. It is not a full annual or interim report, nor is it a call transcript or earnings release. It is not a proxy solicitation or voting results announcement, but rather a formal announcement of board resolutions and nominations. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (over 13,000 characters) and detailed content confirm it is not a brief announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2017-10-09 Chinese
验资报告
Audit Report / Information Classification · 95% confidence The document is titled '验资报告' which translates to 'Capital Verification Report' or 'Audit Report on Capital'. It is issued by an accounting firm (北京兴华会计师事务所) and details the verification of the company's registered capital and share capital changes as of a specific date (2017-09-21). The content includes detailed tables of capital contributions, share capital changes, and audit opinions on the capital increase. This is a standalone audit report focusing on capital verification, not a full annual or interim financial report. It is not an announcement or a brief notice but a detailed audit report on capital verification. Therefore, it fits the category of Audit Report / Information (AR).
2017-09-28 Chinese
关于首期限制性股票激励计划预留部分授予完成登记的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the completion of registration for the first phase of a restricted stock incentive plan by 哈药集团股份有限公司. It details the grant date, number of shares, recipients, adjustments, lock-up periods, performance targets, and the impact on shareholding structure. It also includes a verification report from an accounting firm and a securities registration certificate. The document is a formal announcement of a capital change related to share issuance under a stock incentive plan, not a full financial report or audit report. It does not contain comprehensive financial statements or management discussion but focuses on the share issuance event and related details. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is under 5,000 characters but contains detailed information about the share issuance, so it is not merely a report publication announcement or a regulatory filing. Hence, the classification is SHA with high confidence.
2017-09-28 Chinese
重大事项停牌公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the suspension of trading (停牌公告) due to a major matter involving the controlling shareholder and potential equity changes. It mentions the stock suspension starting from a specific date and the plan to disclose progress every 5 trading days. There is no detailed financial data, no full report, no voting results, no management changes, or other detailed filings. The document is under 5,000 characters and serves as a regulatory announcement about trading suspension and related corporate events. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-09-27 Chinese
七届二十三次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the supervisory board (监事会) of 哈药集团股份有限公司 regarding the resolution on adjusting the recipients and quantities of a restricted stock incentive plan. It details the meeting date, attendance, voting results, and the rationale for the adjustment. The content focuses on corporate governance and internal management decisions related to stock incentives, without presenting financial statements or audit results. It is not a full annual or interim report, nor an earnings release or capital update. It is also not a proxy solicitation or voting result announcement. The document is a formal board/management information announcement about changes in the company's stock incentive plan recipients, which fits best under Board/Management Information (MANG). The document length is short and contains substantive content, not just a report publication announcement or certification. Therefore, the classification is MANG with high confidence.
2017-09-25 Chinese
上海荣正投资咨询有限公司关于哈药集团股份有限公司限制性股票激励计划预留部分调整相关事项之独立财务顾问报告
Regulatory Filings
2017-09-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.